IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
67 hedge funds and large institutions have $63.3M invested in IVERIC bio, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 17 closing their positions.
61% more call options, than puts
Call options by funds: $305K | Put options by funds: $189K
13% more capital invested
Capital invested by funds: $56.3M → $63.3M (+$7.06M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 77 → 67 (-10)
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.6M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$1.15M |
| 3 |
First Manhattan
New York
|
+$1.15M |
| 4 |
Renaissance Technologies
New York
|
+$1.06M |
| 5 |
D.E. Shaw & Co
New York
|
+$693K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$783K |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$706K |
| 3 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$658K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$619K |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$570K |
ISEE Hedge Fund Activity: Q3 2017 in Review
67 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2017, worth a combined $63.3M — up 13% from $56.3M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ISEE and 8 opened new positions — a net loss of 9 holders — while 25 trimmed existing stakes and 18 added.
The largest buyer was Armistice Capital, adding an estimated $2.6M. The largest seller was Goldman Sachs, cutting an estimated $783K.
- 67 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2017, down from 77 in Q2 2017.
- Funds reported $63.3M of IVERIC bio, Inc. Common Stock stock for Q3 2017, up 13% quarter-over-quarter.
- 8 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2017 and 17 closed out, a net change of -9 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q3 2017 was Armistice Capital, an estimated $2.6M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q3 2017 was Goldman Sachs, an estimated $783K sold.
Based on aggregated 13F filings for Q3 2017.